P
ProHub
English 简体中文 繁體中文
Medium Product Launch Market Entry Profitability

Malaria Remedy

#Healthcare #Vaccines
ProHub Comment

This case tests market sizing, breakeven analysis, and competitive positioning in emerging markets. The key challenge is determining which markets are economically viable given high fixed costs and required market penetration rates. The candidate must convert currency units, calculate required market share, and ultimately recognize that Uganda's market dynamics are unfavorable despite higher disease incidence.

Estimated Time 26 minutes
Difficulty Medium
Source ROSS
10 / 100
A team of university researchers based out of Uganda has developed a new vaccine to cure malaria. While there are existing vaccines out there for malaria, the researchers believe that this product has what it takes to be competitive with others in terms of price, accuracy, and reach. They are talking to a pharmaceutical manufacturer named David-Wilson Limited, based out of Ghana, for a potential partnership. In this partnership, David-Wilson will oversee manufacturing and distributing the product, and the researchers will provide the IP rights. David-Wilson Limited has also agreed with the university researchers that it will aim to operate this product at breakeven, to offer the product at the lowest possible price and maximize the number of lives saved. Should the researchers launch the product?

Clarifying Information

  1. What is the business objective of the researchers? Save the greatest number of lives while breaking even in 3 years
  2. Which market are they interested in entering? Their focus will be in the African market
  3. What stage of development & approval is the vaccine currently at? Vaccine has been approved by the equivalent of the FDA in several African countries
  4. What does David-Wilson Limited’s supply chain look like? Their raw materials all come from China, and their factories are all based out of Uganda. They currently ship all their products via trucks
Mock Interview
Interviewer

A team of university researchers based out of Uganda has developed a new vaccine to cure malaria. While there are existing vaccines out there for malaria, the researchers believe that this product has what it takes to be competitive with others in terms of price, accuracy, and reach. They are talking to a pharmaceutical manufacturer named David-Wilson Limited, based out of Ghana, for a potential partnership. In this partnership, David-Wilson will oversee manufacturing and distributing the product, and the researchers will provide the IP rights. David-Wilson Limited has also agreed with the university researchers that it will aim to operate this product at breakeven, to offer the product at the lowest possible price and maximize the number of lives saved. Should the researchers launch the product?

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

University researchers in Uganda developed a malaria vaccine and partnered with David-Wilson Limited (Ghana) for manufacturing and distribution with a breakeven model. The question is whether to launch. Analysis shows Ghana is viable (~62.5% market share needed), Uganda is challenging (~80% needed), and Tanzania is impossible (>100%). Competitive advantages include superior efficacy (95% vs 87% and 80%) but pricing remains a weakness in Uganda.

Key Insights:

  1. Market sizing requires converting local currencies to USD for fair comparison across countries
  2. Breakeven analysis must factor in both annual demand (based on case incidence and purchase rates) and fixed setup costs to determine required market share
  3. High fixed costs relative to market size can make markets unattractive despite large disease burden (South Africa example)
  4. Product quality/efficacy differentiation is valuable but may not overcome pricing disadvantages in price-sensitive markets
  5. Go-to-market strategy should include alternative partners or funding models (NGOs, government) to address cost competitiveness gaps